Pathology Section

The Pathology Section aims to design and conduct translational research in the field of clinical trials. It acts as a platform for the promotion of multicenter studies in the field of pathology. The section is also active in the following areas:

• Quality assurance of clinical studies with regard to pathological diagnoses;
• Review of the initial pathological diagnosis for quality assurance;
• Introduction of novel predictive tests, for example the PIK3CA test for cetuximab treatment or NRAS testing for vemurafenib treatment in melanoma;
• Translational research requires the operation of a tissue bank; pathologists are involved in the establishment of biobanks and the collection of biomaterial.

Outlook

• Development of pathology-based clinical trials;
• Involving pathologists in the early stages of protocol development;
• Informing the pathology community about Swiss Cancer Institute activities involving pathology investigations and translational research.